Source:

Press Release

June 12, 2021
1 min read
Save

Mount Sinai appoints chief of hematology and medical oncology

Source:

Press Release

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Joseph A. Sparano, MD, FACP, has been named chief of hematology and medical oncology at Mount Sinai Health System.

Sparano also will serve as deputy director of The Tisch Cancer Institute and hold the Ezra M. Greenspan, MD professorship in clinical cancer therapeutics at Icahn School of Medicine.

Sparano is recognized for his expertise in the management of breast cancer and HIV-associated malignancies.

Joseph A. Sparano

“Dr. Sparano brings a wealth of experience in clinical, research and educational excellence,” Ramon Parsons, MD, PhD, director of The Tisch Cancer Institute, chair of oncological sciences, and Ward-Coleman chair in cancer research at Icahn Mount Sinai, said in a press release. “He will be instrumental in expanding Mount Sinai’s footprint in cancer advancements, fostering our mission of providing superior cancer care with special attention to equity, and guiding the institution’s progress toward NCI Comprehensive Cancer Center status.”

Sparano spent 33 years at Albert Einstein College of Medicine and Montefiore Medical Center, where he served as professor of medicine; professor of obstetrics, gynecology and women’s health; associate chairman for clinical research in the department of oncology; and associate director for clinical research at Albert Einstein Cancer Center. He also served as chief of the section of breast medical oncology since 1995 and associate chairman of medical oncology since 2001.

Sparano is chair and principal investigator of the AIDS Malignancy Consortium. He has conducted studies designed to improve outcomes of HIV-positive individuals with cancer, including those with non-Hodgkin lymphoma or anal cancer.